These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 19111474)

  • 1. Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization.
    Crea F; Giovannetti E; Zinzani PL; Danesi R
    Crit Rev Oncol Hematol; 2009 Oct; 72(1):21-44. PubMed ID: 19111474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors.
    Danova M; Barni S; Del Mastro L; Danesi R; Pappagallo GL
    Expert Rev Anticancer Ther; 2011 Aug; 11(8):1303-13. PubMed ID: 21916584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy.
    Timmer-Bonte JN; Adang EM; Termeer E; Severens JL; Tjan-Heijnen VC
    J Clin Oncol; 2008 Jan; 26(2):290-6. PubMed ID: 18182670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Febrile neutropenia: highlighting the role of prophylactic antibiotics and granulocyte colony-stimulating factor during standard dose chemotherapy for solid tumors.
    Timmer-Bonte JN; Tjan-Heijnen VC
    Anticancer Drugs; 2006 Sep; 17(8):881-9. PubMed ID: 16940798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bone marrow suppression--including guidelines for the appropriate use of G-CSF].
    Watanabe T
    Gan To Kagaku Ryoho; 2003 Jun; 30(6):755-9. PubMed ID: 12852340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granulocytic growth factors and cancer-related neutropenia: limited effects.
    Prescrire Int; 2006 Oct; 15(85):189-91. PubMed ID: 17128529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children's Oncology Group.
    Ozkaynak MF; Krailo M; Chen Z; Feusner J
    Pediatr Blood Cancer; 2005 Sep; 45(3):274-80. PubMed ID: 15806544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of glycosylated recombinant human granulocyte colony-stimulating factor (lenograstim) use in current cancer treatment: review of clinical data.
    Gunzer K; Clarisse B; Lheureux S; Delcambre C; Joly F
    Expert Opin Biol Ther; 2010 Apr; 10(4):615-30. PubMed ID: 20218922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evidence-based management of neutropenia and fever].
    Ishiguro H; Fung MC; Sakata T; Morizane T; Adachi S
    Gan To Kagaku Ryoho; 2003 Sep; 30(9):1365-71. PubMed ID: 14518423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients.
    Zielinski CC; Awada A; Cameron DA; Cufer T; Martin M; Aapro M
    Eur J Cancer; 2008 Feb; 44(3):353-65. PubMed ID: 18191396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of granulocyte colony stimulating factor (G-CSF) in chemotherapy induced neutropenia.
    Ghalaut PS; Sen R; Dixit G
    J Assoc Physicians India; 2008 Dec; 56():942-4. PubMed ID: 19322972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use and effectiveness of granulocyte colony-stimulating factor in primary prophylaxis for febrile neutropenia in the outpatient setting.
    Tuffaha HW; Treish IM; Zaru L
    J Oncol Pharm Pract; 2008 Sep; 14(3):131-8. PubMed ID: 18524866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Guidelines for prevention of febrile neutropenia].
    Barroso S; Damasceno M; Dinis J; Gervásio H; da Luz R; Passos-Coelho JL; Sá A; Costa L; Rodrigues H; Andrade S; Macedo A; Moital I
    Acta Med Port; 2008; 21(1):7-19. PubMed ID: 18489831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of granulocyte colony-stimulating factor: a survey among Italian medical oncologists.
    Danova M; Rosti G; De Placido S; Bencardino K; Venturini M
    Oncol Rep; 2005 Dec; 14(6):1405-12. PubMed ID: 16273232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines.
    Silvestris N; Del Re M; Azzariti A; Maiello E; Lombardi L; Cinieri S; Guarini A; Brunetti AE; Delcuratolo S; De Vita F; Pisconti S; Danesi R; Colucci G
    Expert Opin Ther Targets; 2012 Apr; 16 Suppl 2():S111-7. PubMed ID: 22443211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Future strategy for cancer treatment using recombinant human granulocyte colony stimulating factor.
    Diehl V
    Eur J Cancer; 1994; 30A Suppl 3():S44-7. PubMed ID: 7535072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endogenous granulocyte colony-stimulating factor (G-CSF) levels in chemotherapy-induced neutropenia and in neutropenia related with primary diseases.
    Kavgaci H; Ozdemir F; Aydin F; Yavuz A; Yavuz M
    J Exp Clin Cancer Res; 2002 Dec; 21(4):475-9. PubMed ID: 12636092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. G-CSF in the prevention of febrile neutropenia in chemotherapy in breast cancer patients.
    Krol J; Paepke S; Jacobs VR; Paepke D; Euler U; Kiechle M; Harbeck N
    Onkologie; 2006 Apr; 29(4):171-8. PubMed ID: 16601374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal use of granulocyte-colony-stimulating factor in patients with cancer who are at risk for chemotherapy-induced neutropenia.
    Cappozzo C
    Oncol Nurs Forum; 2004 May; 31(3):569-76. PubMed ID: 15146222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prevention of febrile neutropenia.
    Pascoe J; Cullen M
    Curr Opin Oncol; 2006 Jul; 18(4):325-9. PubMed ID: 16721125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.